BioCentury
ARTICLE | Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

Biocon is ramping up manufacturing of Alzumab as it prepares to start a large study of the drug

Stephen Hansen, Associate Editor
August 1, 2020 12:45 AM UTC
Updated on Aug 12, 2020 at 9:47 PM UTC
Editor's note: This article has been updated to reflect that the Indian health ministry did not include Alzumab itolizumab among the drugs on its COVID-19 treatment protocol.


Access this Article

BCIQ Company Profiles

Biocon Ltd.